NCT04097938View on ClinicalTrials.gov

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

March 4, 2020

Study Completion Date

July 6, 2020

Conditions
Healthy
Interventions
DRUG

GLPG3667 oral suspension

GLPG3667 oral suspension

DRUG

Placebos

Placebo oral suspension

DRUG

GLPG3667 capsules

GLPG3667 capsules

Trial Locations (1)

2060

SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04097938 - A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 | Biotech Hunter | Biotech Hunter